Associate Professor Michael Patrick Hay

BSc (Hons), PhD

Biography

Michael Hay obtained his BSc (Hons) and PhD in Chemistry from The University of Canterbury, New Zealand. After postdoctoral positions  at Imperial College, London, and the University of Auckland, Michael was appointed as a Research Fellow in the Auckland Cancer Society Research Centre in 1991. He was appointed as an Associate Professor in 2011 and leads a group investigating tumour selective drug delivery targeting the tumour microenvironment. Michael was appointed Director of the ACSRC in 2020. 

Research interests:

Research | Current

Michael is interested in developing novel therapeutics that target the tumour microenvironment through bioreductive mechanisms and/or selective target inhibition. Current research interests include:

  • Discovery of new hypoxia-activated prodrugs
  • Development of nitroimidazole-based radiosensitisers
  • Development of novel agents targeting DNA damage response pathways.
  • Development of hypoxia-selective cytotoxins and radiation response modifiers based on the 1,2,4-benzotriazine dioxide core.
  • Design and synthesis of drugs that target hypoxia-inducible factor (HIF-1alpha).

Distinctions/Honours

Fellow of the New Zealand Institute of Chemistry

Committees/Professional groups/Services

Member of the Medical Committee Auckland Medical Research Foundation

Member of the Biotechnology and Biomedical Sciences Committee, Australian Institute of Nuclear Sciences and Engineering

Selected publications and creative works (Research Outputs)

As of 29 October 2020 there will be no automatic updating of 'selected publications and creative works' from Research Outputs. Please continue to keep your Research Outputs profile up to date.
  • Hendrikse, E. R., Liew, L. P., Bower, R. L., Bonnet, M., Jamaluddin, M. A., Prodan, N., ... Smith, D. M. (2020). Identification of Small-Molecule Positive Modulators of Calcitonin-like Receptor-Based Receptors. ACS pharmacology & translational science, 3 (2), 305-320. 10.1021/acsptsci.9b00108
    Other University of Auckland co-authors: Aqfan Jamaluddin, Keith Richards, Christopher Walker
  • Lee, T. W., Wong, W. W., Dickson, B. D., Lipert, B., Cheng, G. J., Hunter, F. W., ... Wilson, W. R. (2019). Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia. International journal of radiation biology, 95 (12), 1597-1612. 10.1080/09553002.2019.1664787
    Other University of Auckland co-authors: Francis Hunter, Benjamin Dickson, Barbara Lipert, Way Wong
  • Wong, W. W., Jackson, R. K., Liew, L. P., Dickson, B. D., Cheng, G. J., Lipert, B., ... Hay, M. P. (2019). Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361. Biochemical pharmacology, 16910.1016/j.bcp.2019.113641
    Other University of Auckland co-authors: Barbara Lipert, Way Wong, Benjamin Dickson, Yongchuan Gu, Francis Hunter, Lydia Liew
  • Jackson, R. K., Liew, L. P., & Hay, M. P. (2019). Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs. Clinical oncology (Royal College of Radiologists (Great Britain)), 31 (5), 290-302. 10.1016/j.clon.2019.02.004
    Other University of Auckland co-authors: Lydia Liew
  • Dickson, B. D., Wong, W. W., Wilson, W. R., & Hay, M. P. (2019). Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors. Molecules (Basel, Switzerland), 24 (8).10.3390/molecules24081559
    Other University of Auckland co-authors: Benjamin Dickson, Way Wong
  • Liew, L. P., Singleton, D. C., Wong, W. W., Cheng, G. J., Jamieson, S. M. F., & Hay, M. P. (2019). Hypoxia‐Activated Prodrugs of PERK Inhibitors. Chemistry - An Asian Journal, 14 (8), 1238-1248. 10.1002/asia.201801826
    URL: http://hdl.handle.net/2292/48401
    Other University of Auckland co-authors: Lydia Liew, Dean Singleton, Way Wong, Stephen Jamieson
  • Lu, M., Flanagan, J. U., Langley, R. J., Hay, M. P., & Perry, J. K. (2019). Targeting growth hormone function: strategies and therapeutic applications. Signal transduction and targeted therapy, 410.1038/s41392-019-0036-y
    Other University of Auckland co-authors: Ries Langley, Jo Perry, Jack Flanagan
  • Chernikova, S. B., Nguyen, R. B., Truong, J. T., Mello, S. S., Stafford, J. H., Hay, M. P., ... Henry, S. (2018). Dynamin impacts homology-directed repair and breast cancer response to chemotherapy. The Journal of clinical investigation, 128 (12), 5307-5321. 10.1172/jci87191

Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 1, Room 121
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand